Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 3:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,096 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Side Effects Clear all
Enrolling by invitation Phase 3 Interventional

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

NCT05707949
View directory record Official record
Conditions
Migraine Prophylaxis
Interventions
Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
35
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 25, 2026, 3:51 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Efficacy Of "Prodovite®" In Athletic Performance

NCT04734834
View directory record Official record
Conditions
SPORTS NUTRITION
Interventions
"Prodovite®" VMP35
Dietary Supplement
Lead sponsor
Victory Nutrition International, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Charlotte, North Carolina • Huntersville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 25, 2026, 3:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fast Track CSII Using a Novel Device in Young Children With Newly Diagnosed T1DM

NCT00476788
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Omnipod Insulin Management System
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year to 8 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 25, 2026, 3:51 PM EDT
Completed No phase listed Observational

Valproic Acid-associated Hypoalbuminemia in Medically Fragile Patients

NCT00723762
View directory record Official record
Conditions
Hypoalbuminemia
Interventions
Specimen collection
Procedure
Lead sponsor
Akron Children's Hospital
Other
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Mantua, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Oct 25, 2026, 3:51 PM EDT
Terminated No phase listed Observational

Trazodone vs. Quetiapine for the Treatment of ICU Delirium

NCT05307003
View directory record Official record
Conditions
Delirium, Delirium of Mixed Origin, Delirium, Sepsis Associated, Delirium in Old Age, Delirium Confusional State, Psych, Morality, Treatment Side Effects
Interventions
Trazodone, Quetiapine
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 25, 2026, 3:51 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

NCT06318273
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
ABBV-969
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Male only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Duarte, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 25, 2026, 3:51 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

NCT07155174
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
ABBV-706, Atezolizumab, Etoposide, Carboplatin, Lurbinectedin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
12
States / cities
New Haven, Connecticut • Gainesville, Florida • Ocala, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 3:51 PM EDT
Recruiting No phase listed Observational

Global Cardio Oncology Registry

NCT05598879
View directory record Official record
Conditions
Breast Cancer, Hematologic Malignancy, Immune Checkpoint Inhibitor-Related Myocarditis, Cardiotoxicity, Cardiovascular Diseases
Interventions
anonymized data collection during programmed surveillance clinical follow up
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 25, 2026, 3:51 PM EDT
Withdrawn No phase listed Observational

Switching From One Type of Anti-rejection Drug (Tacrolimus or Cyclosporine) to Another (Sirolimus) Approximately 90-180 Days After Liver Transplantation

NCT00834496
View directory record Official record
Conditions
Side Effects of Calcineurin Inhibitors, Renal Toxicity, Hepatic Fibrosis on Biopsy, Neurotoxicity, Post Transplant Diabetes
Interventions
Liver biopsy
Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 25, 2026, 3:51 PM EDT
Recruiting No phase listed Observational

Identification of Genomic Predictors of Adverse Events After Cardiac Surgery

NCT01258231
View directory record Official record
Conditions
Heart; Dysfunction Postoperative, Cardiac Surgery, Genetic Predisposition to Disease, Atrial Fibrillation, Myocardial Infarction, Heart Failure
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
20 Years to 90 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 25, 2026, 3:51 PM EDT
Withdrawn Phase 1 Interventional

Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,Autoimmune, Inflammatory, Neurologic Conditions

NCT02939859
View directory record Official record
Conditions
Multiple Sclerosis, Autoimmune
Interventions
Microcannula Harvest Adipose, Centricyte 1000, Sterile Normal Saline IV deployment AD-cSVF
Procedure · Device
Lead sponsor
Healeon Medical Inc
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Stevensville, Montana
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 25, 2026, 3:51 PM EDT
Active, not recruiting Not applicable Interventional

The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now

NCT05591066
View directory record Official record
Conditions
Communication
Interventions
PFC I-PASS+ Intervention
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
14,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 3:51 PM EDT
Not listed No phase listed Observational

National Vaccine Adverse Event Reporting Survey and Etiology

NCT05095844
View directory record Official record
Conditions
COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
Interventions
vaccinated
Biological
Lead sponsor
Neuroganics LLC
Industry
Eligibility
5 Years to 99 Years
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Northglenn, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 25, 2026, 3:51 PM EDT
Terminated Phase 1 Interventional Results available

A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery

NCT05446129
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Ezabenlimab, BI 765063, Pembrolizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 25, 2026, 3:51 PM EDT
Completed No phase listed Observational Results available

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

NCT01266265
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
Not listed
Enrollment
1,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
88
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 25, 2026, 3:51 PM EDT
Not yet recruiting Phase 1 Interventional

Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity

NCT07838649
View directory record Official record
Conditions
Lymphoma Cancer, Breast Cancer, Cancer of the Breast, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
68Ga-Galmydar, PET/MRI, 18F-FDG
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 3:51 PM EDT
Completed Not applicable Interventional

Randomized, Double-Blind Cross-Over Trial Of Buprenorphine and Low-Dose Naloxone Versus Buprenorphine

NCT00679458
View directory record Official record
Conditions
Pain
Interventions
buprenorphine and low-dose naloxone, buprenorphine alone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Oct 25, 2026, 3:51 PM EDT
Completed Not applicable Interventional Results available

Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate

NCT02665117
View directory record Official record
Conditions
Hypertension
Interventions
Potassium Magnesium Citrate (KMgCit), Potassium Chloride (KCl), Chlorthalidone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
3
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 25, 2026, 3:51 PM EDT
Completed Phase 4 Interventional Results available

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

NCT01336140
View directory record Official record
Conditions
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 25, 2026, 3:51 PM EDT
Completed Phase 1 Interventional

Effect of AdhAQP1 on Salivary Flow in Patients Treated With Radiation for Head and Neck Cancer

NCT00372320
View directory record Official record
Conditions
Parotid Salivary Dysfunction
Interventions
Gene Transfer, AdhAQP1
Genetic · Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 25, 2026, 3:51 PM EDT
Completed No phase listed Observational

The Efficacy Side Effects and the Tolerance of Polyethylene Glycol 3350 as a Bowel Prep in Children

NCT01164410
View directory record Official record
Conditions
Colonoscopy
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
5 Years to 21 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Oct 25, 2026, 3:51 PM EDT
Completed Not applicable Interventional

The Effect of Transcranial Direct Current Stimulation on Cognitive Side Effects of Electroconvulsive Therapy

NCT02897843
View directory record Official record
Conditions
Depressive Disorder
Interventions
transcranial magnetic stimulation, sham tDCS
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 25, 2026, 3:51 PM EDT
Not listed Phase 2 Interventional

Pilot Study of High-Concentration Capsaicin Patches in the Treatment of Painful HIV-Associated Neuropathy

NCT00061152
View directory record Official record
Conditions
HIV Infections
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
West Hollywood, California • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 14, 2007 · Synced Oct 25, 2026, 3:51 PM EDT
Completed No phase listed Observational

Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab

NCT00875238
View directory record Official record
Conditions
Breast Cancer, Cardiac Toxicity, Cardiovascular Complications
Interventions
trastuzumab, doxorubicin hydrochloride, polymorphism analysis, laboratory biomarker analysis, questionnaire administration, assessment of therapy complications, magnetic resonance imaging
Biological · Drug · Genetic + 2 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
4
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 25, 2026, 3:51 PM EDT